- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
S&P 500 (NYSE:SPY) component Celgene (NASDAQ:CELG) will unveil its latest earnings tomorrow, Thursday, January 24, 2013. Celgene is a biopharmaceutical company that develops innovative therapies to treat cancer and immune-inflammatory related diseases.
Celgene Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average analyst estimate is for net income of $1.18 per share, a rise of 21.6% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved down from $1.19. Between one and three months ago, the average estimate moved down. It has been unchanged at $1.18 during the last month. For the year, analysts are projecting profit of $4.42 per share, a rise of 28.9% from last year.
Past Earnings Performance: Last quarter, the company beat estimates by 3 cents, coming in at net income of $1.19 per share against an estimate of profit of. The company also topped expectations in the second quarter.
Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!
Here’s how Celgene traded following its last earnings report 3 months ago and leading up to its upcoming earnings report this week:
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.